Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Q1 2026 Earnings Presentation
33 slides from Qt Imaging's earnings presentation, May 13, 2026
Slide 1: Quantitative Transmission Imaging
NASDAQ:QTI Quantitative Transmission Imaging Breast Acoustic CT Scanner May 2026 Copyright ©2026 QT Imaging, Inc. All Rights Reserved.
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respecti
Slide 3: Disclaimer: Forward Looking Statements
Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generall
Slide 4: Our Mission: Transforming Breast Health For Every Woman
Our Mission Transforming Breast Health For Every Woman At QT Imaging, we are redefining what’s possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the firs
Slide 5: QT Imaging Transformation
QT Imaging Transformation $18M from NIH to develop QTI becomes Approval of supplemental imaging modality public on Raise Reimbursement to resolve dense breasts NASDAQ $18M PIPE Category III CPT Code 2012-2025 Mar 2024 Oct 2025 Feb 2026 2012 2017 Feb 2025 Jan 2026 Company FDA QTI gets delisted, Relis
Slide 6: The Pain and Why QT Imaging
The Pain and Why QT Imaging The Pain Why QT Imaging • Mammography misses cancers in • QT Imaging has uniquely dense breasts / it is painful. differentiated solution • MRI is expensive / slow / uncomfortable • Accurate diagnosis in dense breasts / contract injection • Product is validated and FDA cle
Slide 7: Accurate Imaging for Dense Breasts
Accurate Imaging for Dense Breasts Today’s Challenge: QT Imaging Solution: Multi-step, patient anxiety and attrition Single step (Supplemental + Dx) patient prone process with high number of friendly process, with potential to reduce unnecessary biopsies unnecessary biopsies Primary Breast Density S
Slide 8: QT Imaging Value Proposition
QT Imaging Value Proposition For the Patient For the Clinician For the Administrator • One-stop-shop supplemental • One test – multiple results • 2.5 X more revenue per scan + diagnostic imaging (MRI like Imaging) compared to mammography + handheld ultrasound • Calcium visualization (DCIS + Ca, • No
Slide 9: Our Technology and Product
Our Technology and Product • FDA-cleared, patent protected breast imaging modality • Pain free, safe, no radiation or contrast • Inherently 3D quantitative, imaging modality, thus it’s high resolution, similar to MRI • Two independent sources of information: − CT-like configuration with ultrasound t
Slide 10: Optimized Patient Experience
Optimized Patient Experience PerfeQTion Imaging Center • No ionizing radiation. Acoustic source only Haverford, PA • No breast compression and associated discomfort • 10-12 minutes per breast exam time • Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams) •
Slide 11: Quantitative Imaging Platform Enables AI and Biomarker Expansion
Quantitative Imaging Platform Enables AI and Biomarker Expansion Biomarker Development Cloud-Based AI Integration • Unique quantitative data: Speed of Sound, • Deployment within QTI Cloud SaaS Attenuation, Reflection, Nakagami parameters etc. Integration via InteleShare’s framework • Early detection
Slide 12: Our Market, Why Now, and How It Fits In
Our Market, Why Now, and How It Fits In
Slide 13: QT Imaging's Technology Has the Opportunity to Transform the Breast Imaging Market
QT Imaging’s Technology Has the Opportunity to Transform the Breast Imaging Market CURRENT MARKET NEW MARKET 2025 2030 Breast Imaging: Layer Description CAGR SaaS Biomarkers: Value Value $6B MARKET (1) $1B MARKET (3) • FDA approved as supplemental Total global opportunity • Move to personalized, scr
Slide 14: FDA Density Disclosure Requirements
FDA Density Disclosure Requirements Many Women Have Dense Breasts, The FDA Has Recognized the Which Mammograms are Inefficient Importance of Breast Density in Screening for Cancer in Breast Cancer Screening 50% of women between 50% 50% the ages of 40-74 in the U.S. have dense breasts(1) (3) QTscan i
Slide 15: AI Adoption in Radiology and Personalized Oncology/Biomarkers
AI Adoption in Radiology and Personalized Oncology/Biomarkers Radiology is the leading specialty for clinical Oncology is moving from one-size-fits-all treatment AI adoption toward biomarker-guided therapy • ~30 to 48% of radiologists report active clinical • Precision oncology increasingly relies o
Slide 16: Category III CPT Code Approval – X579T
Category III CPT Code Approval – X579T • Submitted on November 3, 2025 • Approved by AMA in February 2026 • Scheduled for release on July 1, 2026, with an effective date of January 1, 2027 ➢The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancemen
Slide 17: Breast Cancer Screening Matrix: QT Imaging Sweet Spot
Breast Cancer Screening Matrix: QT Imaging Sweet Spot Risk Category (Tyrer-Cuzick Lifetime Risk) Typical Risk Profile Description < 40 Years ≥ 40 Years + Breast Density No first-degree relatives with breast cancer No known pathogenic mutations Mammography Low Risk (<12%) No routine imaging; No prior
Slide 18: Validation
y QT IMAGING Validation
Slide 19: Validation
Validation • Existing FDA clearance to offer an imaging modality for all patients above 18 years old NIH has awarded QT • Received UAE regulatory approval Imaging about • NIH $18M funding to generate a safe imaging $18M for new women’s modality for women with dense breasts imaging solution • Ongoing
Slide 20: Clinical Validation: Mayo Clinic – QTscan vs MRI
Clinical Validation Across Screening and Oncology Applications: Mayo Clinic – QTscan vs MRI QT Scan • Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QTscan) with breast MRI for supplemental screening • Strong breast-level agreement with MRI: binary agreement betw
Slide 21: Clinical Validation: Sunnybrook Cancer Center – QTscan vs MRI
Clinical Validation Across Screening & Oncology Applications: Sunnybrook Cancer Center – QTscan vs MRI QT Scan • NIH/NCI-funded, to prove QT Imaging as imaging modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC) • Major oncology need: − treatment response that c
Slide 22: Regulatory Activities Additional to FDA Clearance
Regulatory Activities Additional to FDA Clearance Saudi FDA (SFDA) Submit Dossier —Feb, 2026 Expected Marketing Under SFDA Authorized Rep via Gulf Medical; Authorization Regulatory Review MDS-GS-004 Target: Q2 2026 UAE MOHAP Dossier Preparation UAE Submission Approval early! Leverage SFDA submission
Slide 23: Business Model, Partnerships & Financial Trajectory
Business Model, Partnerships & Financial Trajectory
Slide 24: Business Model
Business Model HW+ SaaS +AI Diagnostic Layer Cloud SaaS Platform Business Model: • Hardware sale (scanner): upfront revenue • SaaS platform: Radiology Referring MD recurring revenue • AI diagnostic layer: higher margin Hardware gets us in the door. Software builds the company. Copyright ©2026 QT Ima
Slide 25: Business Partnerships Today
Business Partnerships Today Under Distribution Under Contract Under Distribution Under Distribution Agreement with Manufacturing Agreement with Gulf Agreement with Al NXC Imaging Agreement with Medical for Kingdom Naghi Medical for the (Subsidiary of Canon Canon Medical of Saudi Arabia (KSA) United
Slide 26: Business Partnerships: U.S. and International Expansion
Business Partnerships U.S. and International Expansion • Under Distribution Agreement • Under Distribution Agreement • Under Distribution Agreement with NXC Imaging (Subsidiary with Gulf Medical for KSA market with Al Naghi Medical for the of Canon Medical Systems) for − Committed MOQs for scanner U
Slide 27: QTI Precision Pathway – Cloud SaaS Platform
QTI Precision Pathway – Cloud SaaS Platform Core Operational Advanced Enterprise System software Collaboration & Quantitated Multiuser access updates data sharing biomarkers Enterprise Long term technology Automated analysis collaboration relevance Precision reporting Biomarker / Analysis QTI Precis
Slide 28: Financial Trajectory
Financial Trajectory Yearly Revenue and Scanner Shipments Quarterly Revenue and Scanner Shipments 17 $45.0 90 $9.00 18 $39.0 $40.0 80 $8.00 16 13 $7.00 14 $35.0 70 $6.00 12 Shipments (#) Revenue ($M) $30.0 60 Shipments (#) Revenue ($M) 9 $5.00 8 10 $25.0 50 $18.9 $4.00 8 6 $20.0 40 $3.00 4 4 6 $15.0
Slide 29: Financial Trajectory: Revenue/Scanner, Gross Margin, Unit Economics
Financial Trajectory Revenue/scanner, Gross Margin, and Unit Economics (Adjusted EBITDA/Scanner) $600 100% $473 $488 $500 $407 80% $400 54% 60% $300 45% 45% $200 40% $100 20% $8 $- 0% $(100) $(88) -20% $(200) $(300) -40% $(400) -60% $(500) -80% $(600) $(700) $(613) -100% FY 2024 A FY 2025 A FY 2026
Slide 30: Competitive Sales Cycle and Clinical Sites Adoption Curve
Competitive Sales Cycle and Clinical Sites Adoption Curve Segment/ Existing Imaging QT Imaging Sales Cycle Equipment Equipment Hospital 12 to 18 months 6 to 8 months Outpatient 6 to 12 months 4 to 6 months Imaging Functional 6 to 8 months Medicine (cash pay) QT Imaging’s differentiated value proposi
Slide 31: Planned Evolution to Hybrid Commercial Model as Scale Increases
Planned Evolution to Hybrid Commercial Model as Scale Increases 2026 2027-2028 Long term Distributor Led Hybrid Model Selective Direct Sales • Broad market coverage • Direct ownership of highest value • Direct leads strategic accounts • Capital efficient accounts • Distributor supports service • Rap
Slide 32: QT Imaging Is Executing on Its Early Commercial Scale
QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points • FDA cleared, clinically validated technology addressing a large unmet need in dense breast imaging – this is a category-defining company at the exact moment the market is ready • Commercial infras
Slide 33: Thank You!
y QT IMAGING Thank You!